Zealand Pharma AS (ZLDPF)
135.65
+2.24
(+1.68%)
USD |
OTCM |
Sep 20, 16:00
Zealand Pharma PS Ratio: 153.63 for Sept. 20, 2024
PS Ratio Chart
Historical PS Ratio Data
| Date | Value |
|---|---|
| September 20, 2024 | 153.63 |
| September 19, 2024 | 151.10 |
| September 18, 2024 | 151.10 |
| September 17, 2024 | 152.57 |
| September 16, 2024 | 152.57 |
| September 13, 2024 | 154.89 |
| September 12, 2024 | 148.15 |
| September 11, 2024 | 149.49 |
| September 10, 2024 | 142.42 |
| September 09, 2024 | 141.57 |
| September 06, 2024 | 143.30 |
| September 05, 2024 | 140.53 |
| September 04, 2024 | 144.97 |
| September 03, 2024 | 142.70 |
| August 30, 2024 | 142.70 |
| August 29, 2024 | 142.70 |
| August 28, 2024 | 142.70 |
| August 27, 2024 | 144.40 |
| August 26, 2024 | 144.40 |
| August 23, 2024 | 148.05 |
| August 22, 2024 | 149.78 |
| August 21, 2024 | 151.00 |
| August 20, 2024 | 150.04 |
| August 19, 2024 | 152.44 |
| August 16, 2024 | 160.53 |
| Date | Value |
|---|---|
| August 15, 2024 | 155.15 |
| August 14, 2024 | 155.16 |
| August 13, 2024 | 150.63 |
| August 12, 2024 | 142.40 |
| August 09, 2024 | 147.57 |
| August 08, 2024 | 143.04 |
| August 07, 2024 | 142.70 |
| August 06, 2024 | 140.55 |
| August 05, 2024 | 134.29 |
| August 02, 2024 | 148.81 |
| August 01, 2024 | 148.81 |
| July 31, 2024 | 150.64 |
| July 30, 2024 | 149.88 |
| July 29, 2024 | 142.80 |
| July 26, 2024 | 146.38 |
| July 25, 2024 | 153.64 |
| July 24, 2024 | 147.22 |
| July 23, 2024 | 145.94 |
| July 22, 2024 | 143.71 |
| July 19, 2024 | 142.70 |
| July 18, 2024 | 141.45 |
| July 17, 2024 | 142.70 |
| July 16, 2024 | 154.38 |
| July 15, 2024 | 153.48 |
| July 12, 2024 | 152.90 |
Price to Sales Ratio Definition
The Price to Sales Ratio (PS Ratio) is calculated by taking the stock price / revenue per share (ttm). This metric is considered a valuation metric that confirms whether the sales of a company justifies the stock price. There isn't necesarily an optimum PS ratio, since different industries will have different ranges of PS Ratios. Because of this, PS Ratio is great to evaluate from a relative standpoint with other similar companies. PS Ratio might also be a handy metric for companies that are not profitable yet, since they might be valued moreso by their overall sales and potential of becoming profitable in the future.
PS Ratio Range, Past 5 Years
26.38
Minimum
May 11 2022
34151.56
Maximum
Sep 29 2021
1114.66
Average
78.23
Median
PS Ratio Benchmarks
| Novo Nordisk AS | 15.25 |
| Eli Lilly and Co | 21.38 |
| Altimmune Inc | 1208.78 |
| Genmab AS | 6.089 |
| Viking Therapeutics Inc | -- |
PS Ratio Related Metrics
| Price to Book Value | 7.134 |
| Price | 135.65 |
| Earnings Yield | -1.25% |
| Market Cap | 9.622B |